-
Je něco špatně v tomto záznamu ?
An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries
S. Rollefstad, E. Ikdahl, G. Wibetoe, J. Sexton, CS. Crowson, P. van Riel, GD. Kitas, I. Graham, SR. Dahlqvist, G. Karpouzas, E. Myasoedova, MA. Gonzalez-Gay, PP. Sfikakis, MG. Tektonidou, A. Lazarini, D. Vassilopoulos, B. Kuriya, CA. Hitchon,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
PubMed Central
od 2015
ProQuest Central
od 2016-10-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2016-10-01 do Před 1 rokem
Oxford Journals Open Access Collection
od 2015-01-01
PubMed
34232315
DOI
10.1093/ehjcvp/pvab052
Knihovny.cz E-zdroje
- MeSH
- dyslipidemie * diagnóza farmakoterapie epidemiologie MeSH
- hypertenze * diagnóza farmakoterapie epidemiologie MeSH
- kardiovaskulární nemoci * diagnóza epidemiologie prevence a kontrola MeSH
- lidé MeSH
- lipidy MeSH
- revmatoidní artritida * diagnóza farmakoterapie epidemiologie MeSH
- rizikové faktory MeSH
- statiny * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
AIMS: To assess differences in estimated cardiovascular disease (CVD) risk among rheumatoid arthritis (RA) patients from different world regions and to evaluate the management and goal attainment of lipids and blood pressure (BP). METHODS AND RESULTS: The survey of CVD risk factors in patients with RA was conducted in 14 503 patients from 19 countries during 2014-19. The treatment goal for BP was <140/90 mmHg. CVD risk prediction and lipid goals were according to the 2016 European guidelines. Overall, 21% had a very high estimated risk of CVD, ranging from 5% in Mexico, 15% in Asia, 19% in Northern Europe, to 31% in Central and Eastern Europe and 30% in North America. Of the 52% with indication for lipid-lowering treatment (LLT), 44% were using LLT. The lipid goal attainment was 45% and 18% in the high and very high risk groups, respectively. Use of statins in monotherapy was 24%, while 1% used statins in combination with other LLT. Sixty-two per cent had hypertension and approximately half of these patients were at BP goal. The majority of the patients used antihypertensive treatment in monotherapy (24%), while 10% and 5% as a two- or three-drug combination. CONCLUSION: We revealed considerable geographical differences in estimated CVD risk and preventive treatment. Low goal attainment for LLT was observed, and only half the patients obtained BP goal. Despite a high focus on the increased CVD risk in RA patients over the last decade, there is still substantial potential for improvement in CVD preventive measures.
1st Medical Faculty Charles University Prague Czech Republic
5 A Nasonova Research Institute of Rheumatology Moscow Russia
Bernhoven Hospital Uden the Netherlands
Center of Cardiology of Russian Ministry of Healthcare Moscow Russia
Department of Internal Medicine University of Manitoba Winnipeg Manitoba Canada
Department of Medicine Division of Rheumatology University of Toronto Toronto Ontario Canada
Department of Rheumatology and Immunology Peking University People's Hospital Beijing 100044 China
Division of Rheumatology Department of Internal Medicine Mayo Clinic Rochester MN USA
Dudley Group NHS Foundation Trust Dudley West Midlands UK
Hospital Universitario 'Dr José E González' UANL Monterrey México
Hospital Universitario Marqués de Valdecilla Santander Spain
Iii Interna klinika fn Olomouc Olomouc Czech Republic
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán México City México
Ivanovo State Medical Academy Ivanovo Russia
Kyrgyz State Medical Academy Bishkek Kyrgyz Republic
National Institute of Rheumatic Diseases 92101 Piešťany Slovensko Slovakia
Spedali Civili and University of Brescia Brescia Italy
Swedish Rheumatoid Arthritis Registry Umeå Sweden
Tallagh University Hospital Dublin Ireland
The Lundquist Institute Harbor UCLA Medical Center Torrance CA USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22024475
- 003
- CZ-PrNML
- 005
- 20221031100256.0
- 007
- ta
- 008
- 221017s2022 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/ehjcvp/pvab052 $2 doi
- 035 __
- $a (PubMed)34232315
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Rollefstad, Silvia $u Preventive Cardio-Rheuma Clinic, Division of Rheumatology and Research, Diakonhjemmet Hospital, Diakonveien 12, 0370 Oslo, Norway $1 https://orcid.org/0000000267133241
- 245 13
- $a An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries / $c S. Rollefstad, E. Ikdahl, G. Wibetoe, J. Sexton, CS. Crowson, P. van Riel, GD. Kitas, I. Graham, SR. Dahlqvist, G. Karpouzas, E. Myasoedova, MA. Gonzalez-Gay, PP. Sfikakis, MG. Tektonidou, A. Lazarini, D. Vassilopoulos, B. Kuriya, CA. Hitchon, MS. Stoenoiu, P. Durez, V. Pascual-Ramos, DA. Galarza-Delgado, P. Faggiano, DP. Misra, A. Borg, R. Mu, EM. Mirrakhimov, D. Gheta, S. Myasoedova, L. Krougly, T. Popkova, A. Tuchyňová, M. Tomcik, M. Vrablik, J. Lastuvka, P. Horák, H. Medková, AG. Semb
- 520 9_
- $a AIMS: To assess differences in estimated cardiovascular disease (CVD) risk among rheumatoid arthritis (RA) patients from different world regions and to evaluate the management and goal attainment of lipids and blood pressure (BP). METHODS AND RESULTS: The survey of CVD risk factors in patients with RA was conducted in 14 503 patients from 19 countries during 2014-19. The treatment goal for BP was <140/90 mmHg. CVD risk prediction and lipid goals were according to the 2016 European guidelines. Overall, 21% had a very high estimated risk of CVD, ranging from 5% in Mexico, 15% in Asia, 19% in Northern Europe, to 31% in Central and Eastern Europe and 30% in North America. Of the 52% with indication for lipid-lowering treatment (LLT), 44% were using LLT. The lipid goal attainment was 45% and 18% in the high and very high risk groups, respectively. Use of statins in monotherapy was 24%, while 1% used statins in combination with other LLT. Sixty-two per cent had hypertension and approximately half of these patients were at BP goal. The majority of the patients used antihypertensive treatment in monotherapy (24%), while 10% and 5% as a two- or three-drug combination. CONCLUSION: We revealed considerable geographical differences in estimated CVD risk and preventive treatment. Low goal attainment for LLT was observed, and only half the patients obtained BP goal. Despite a high focus on the increased CVD risk in RA patients over the last decade, there is still substantial potential for improvement in CVD preventive measures.
- 650 12
- $a revmatoidní artritida $x diagnóza $x farmakoterapie $x epidemiologie $7 D001172
- 650 12
- $a kardiovaskulární nemoci $x diagnóza $x epidemiologie $x prevence a kontrola $7 D002318
- 650 12
- $a dyslipidemie $x diagnóza $x farmakoterapie $x epidemiologie $7 D050171
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a statiny $7 D019161
- 650 12
- $a hypertenze $x diagnóza $x farmakoterapie $x epidemiologie $7 D006973
- 650 _2
- $a lipidy $7 D008055
- 650 _2
- $a rizikové faktory $7 D012307
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Ikdahl, Eirik $u Preventive Cardio-Rheuma Clinic, Division of Rheumatology and Research, Diakonhjemmet Hospital, Diakonveien 12, 0370 Oslo, Norway
- 700 1_
- $a Wibetoe, Grunde $u Preventive Cardio-Rheuma Clinic, Division of Rheumatology and Research, Diakonhjemmet Hospital, Diakonveien 12, 0370 Oslo, Norway
- 700 1_
- $a Sexton, Joe $u Preventive Cardio-Rheuma Clinic, Division of Rheumatology and Research, Diakonhjemmet Hospital, Diakonveien 12, 0370 Oslo, Norway
- 700 1_
- $a Crowson, Cynthia S $u Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA $u Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
- 700 1_
- $a van Riel, Piet $u Bernhoven Hospital, Uden, the Netherlands
- 700 1_
- $a Kitas, George D $u Dudley Group NHS Foundation Trust, Dudley, West Midlands, UK
- 700 1_
- $a Graham, Ian $u Trinity College Dublin, Dublin, Ireland $1 https://orcid.org/0000000209794674
- 700 1_
- $a Dahlqvist, Solbritt Rantapää $u Swedish Rheumatoid Arthritis Registry, Umeå, Sweden
- 700 1_
- $a Karpouzas, George $u The Lundquist Institute, Harbor-UCLA Medical Center, Torrance, CA, USA
- 700 1_
- $a Myasoedova, Elena $u Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
- 700 1_
- $a Gonzalez-Gay, Miguel A $u Hospital Universitario Marqués de Valdecilla, Santander, Spain
- 700 1_
- $a Sfikakis, Petros P $u Joint Rheumatology Program, First Department of Propaedeutic Internal Medicine, Laiko Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Tektonidou, Maria G $u Joint Rheumatology Program, First Department of Propaedeutic Internal Medicine, Laiko Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Lazarini, Argyro $u Joint Rheumatology Program, 2nd Department of Medicine and Laboratory, Hippokration General Hospital, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Vassilopoulos, Dimitrios $u Joint Rheumatology Program, 2nd Department of Medicine and Laboratory, Hippokration General Hospital, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Kuriya, Bindee $u Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada
- 700 1_
- $a Hitchon, Carol A $u Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
- 700 1_
- $a Stoenoiu, Maria Simona $u Rheumatology Department, Cliniques Universitaires Saint Luc, Institut de recherche expérimentale et clinique, Université catholique de Louvain, Brussels, Belgium
- 700 1_
- $a Durez, Patrick $u Rheumatology Department, Cliniques Universitaires Saint Luc, Institut de recherche expérimentale et clinique, Université catholique de Louvain, Brussels, Belgium
- 700 1_
- $a Pascual-Ramos, Virginia $u Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, México
- 700 1_
- $a Galarza-Delgado, Dionicio Angel $u Hospital Universitario 'Dr José E. González', UANL, Monterrey, México
- 700 1_
- $a Faggiano, Pompilio $u Spedali Civili and University of Brescia, Brescia, Italy
- 700 1_
- $a Misra, Durga Prasanna $u Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, Uttar Pradesh, India
- 700 1_
- $a Borg, Andrew $u Mater Dei, Msida, Malta
- 700 1_
- $a Mu, Rong $u Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China
- 700 1_
- $a Mirrakhimov, Erkin M $u Kyrgyz State Medical Academy, Bishkek, Kyrgyz Republic
- 700 1_
- $a Gheta, Diane $u Tallagh University Hospital, Dublin, Ireland
- 700 1_
- $a Myasoedova, Svetlana $u Ivanovo State Medical Academy, Ivanovo, Russia
- 700 1_
- $a Krougly, Lev $u Center of Cardiology of Russian Ministry of Healthcare, Moscow, Russia
- 700 1_
- $a Popkova, Tatiana $u V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
- 700 1_
- $a Tuchyňová, Alena $u National Institute of Rheumatic Diseases, 92101 Piešťany, Slovensko, Slovakia
- 700 1_
- $a Tomcik, Michal $u Institute of Rheumatology, Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Vrablik, Michal $u Third Department of Internal Medicine, Department of Endocrinology and Metabolism, First Medical Faculty, Charles University and General Faculty Hospital, Prague, Czech Republic
- 700 1_
- $a Lastuvka, Jiri $u Third Department of Internal Medicine, Department of Endocrinology and Metabolism, First Medical Faculty, Charles University and General Faculty Hospital, Prague, Czech Republic $u First Medical Faculty, Charles University, Prague, Czech Republic
- 700 1_
- $a Horák, Pavel $u Iii Interna klinika fn Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Medková, Helena $u Division of Rheumatology, 2nd Department of Internal Medicine-Gastroenterology, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Hradec Králové, Czech Republic
- 700 1_
- $a Semb, Anne Grete $u Preventive Cardio-Rheuma Clinic, Division of Rheumatology and Research, Diakonhjemmet Hospital, Diakonveien 12, 0370 Oslo, Norway
- 773 0_
- $w MED00195025 $t European heart journal. Cardiovascular pharmacotherapy $x 2055-6845 $g Roč. 8, č. 6 (2022), s. 539-548
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34232315 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031100254 $b ABA008
- 999 __
- $a ok $b bmc $g 1854279 $s 1175765
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 8 $c 6 $d 539-548 $e 2022Sep03 $i 2055-6845 $m European heart journal. Cardiovascular pharmacotherapy $n Eur Heart J Cardiovasc Pharmacother $x MED00195025
- LZP __
- $a Pubmed-20221017
